Tagrisso 80mg Tablets| Osimeritinib Uses & Side effects

1. OSIMERITINIB 80MG |TAGRISSO 80MG | MILLIONHEALTHPHARMA DESCRIPTION Tagrisso 80mg A Tagrisso 80mg tablet is containing an active substance known as Osimeritinib, which is formerly known as Mereletinib. Tagrisso 80mg is considered as third generation medicine, which is available in tablet form. Tagrisso 80mg is an inevitable, selectively deviated epidermal growth factor receptor prohibitor, containing anti-cancer activity. The pharmacological category of Tagrisso 80mg tablet is tyrosine kinase prohibitor.

2. INDICATION TAGRISSO 80MG A Tagrisso 80mg tablet is widely indicated as first line therapy for advanced non-small cell lung cancer with EGFR mutation positive patients. Tagrisso 80mg tablet is also used for the treatment of patients affected with advanced EGFR T792M mutation positive NSCLC, disease has advanced on or after the tyrosine kinase inhibitor treatment. MECHANISM OF ACTION

3. PROPERTIES Ingredients : Bevacizumab Strength : 100mg/4ml Package : 400mg of Bevacizumab containing vial ADME PROPERTIES Absorption : High plasma concentration time of Osimeritinib reaches within 6 hours Distribution : Volume of distribution 918L Human Plasma protein bound to Osimeritinib is 95% Metabolism : The metabolism of Osimeritinib is occurs via oxidation. The Two pharmacologically active metabolite of Osimeritinib are AZ7550 & AZ5104 Excretion : The mean terminal half-life period 48 hours Clearance value 14.3L/hr 68% of metabolite is excreted in feces; 14% through urine 2% of unchanged form of drug is eliminated

4. DOSAGE MANAGEMENT The recommended dosage of Tagrisso 80mg tablets are, 80mg tablet should be taken as a single dose. Tagrisso tablet should be administered with or without food. If patient felt difficult to swallow the Tagrisso tablets as such, must disperse the tablet in 60ml of noncarbonated water and drink the solution immediately. Tagrisso tablet do not break, crush or chew. Interrupt the treatment during the conditions like; Interstitial lung disease QT prolongation Symptomatic congestive heart failure In pain management Grade III or severe: discontinue the Tagrisso tablet for 3 weeks Grade 0 to II: follow at 80mg or 40mg as a single dose

5. If no development in 3 weeks: Discontinue the therapy. While co administration of Tagrisso with CYP3A4 inducers, the dosage of Tagrisso 80mg should be increased to 160mg as a single dose and followed by 80mg for 3 weeks after discontinuation of strong CYP3A4 inducers. PRECAUTIONS Interstitial lung disease: To avoid this problem, withheld or stop the Tagrisso 80mg tablets. Keratitis: check the manifestation of keratitis regularly and provide supportive measures

6. Embryo fetal toxicity: Tagrisso 80mg tablet required in pregnancy period causes fetal damage. QTc extension: Do not concurrent use of Tagrisso 80mg with drug prolong the QTc Cardiomyopathy: Periodic cardiac monitoring is assessed; in this condition stop the therapy. SIDE EFFECTS The most common adverse effects occurred during the therapy; Cardiomyopathy, QT prolongation, Interstitial lung disease, Keratitis. Other common side effect : Diarrhea or constipation, Hyperglycemia, Hypomagnesemia, Hyponatremia, Elevation of AST & ALT, Stomatitis, Nausea, Vomiting, Rash, Nail toxicity, Pruritus, Dry skin, Headache, Cough,

7. Dyspnea, Fatigue, Pyrexia, Loss of appetite, Respiratory tract infection, Lymphopenia, Thrombocytopenia, Anemia, Neutropenia. PREGNANCY Pregnancy category of Osimeritinib is not designate While using Tagrisso 80mg tablet causes possible for fetal harm. LACTATION Milk feeding should not be taken during lactation period. STORAGE The Tagrisso 80mg tablet is, stored at 25°C. Keep the tablet carton from moisture, heat and light. MISSED DOSE In case of missed dose, do not take the missed dose and follow the regular dosing schedule. CONTACT US PHONE NO:+91-9940472902 EMAIL :millionhealthpharmaceuticals@gmail.com WEBSITE :https://millionpharma.com/osimeritinib-80mg.php